Wir sind mit live! Mehr erfahren

Merck

MRK

Börsenwert 360 Mrd. $

145,95 USD

+0,76

0,52 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

145,26

-0,69

0,47 %

1 Tag

0,52 %

5 Tage

0,14 %

1 Monat

0,72 %

3 Monate

14,35 %

6 Monate

26,41 %

Seit Jahresbeginn

37,11 %

1 Jahr

73,92 %

5 Jahre

89,18 %

10 Jahre

148,64 %

Profil: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Mitarbeiter: 75.000

Gesundheitswesen Arzneimittelhersteller – allgemein

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 53,3 %

Neutral 37,9 %

Negativ 8,7 %

Investors Business Daily

Merck Stock: Watch This Price, Prepare To Profit From This Trade

Merck stock has been in an uptrend. A bullish options strategy aims to profit if the drugmaker's stock keeps rising.

Merck Stock: Watch This Price, Prepare To Profit From This Trade

24/7 Wall Street

The Stocks That Will Get Investors Home Safe When Tech Cracks

When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized.

The Stocks That Will Get Investors Home Safe When Tech Cracks

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.

Why Healthcare Stocks Are Hot When the AI Trade Runs Cold

The Big 3: MRK, GILD, XOM

The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.

The Big 3: MRK, GILD, XOM

24/7 Wall Street

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Zacks Investment Research

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex system," but said Merck and Moderna have the process "down to a very tight science.

Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

Zacks Investment Research

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.

Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

Zacks Investment Research

Merck (MRK) Dips More Than Broader Market: What You Should Know

Merck (MRK) concluded the recent trading session at $141.98, signifying a -2.39% move from its prior day's close.

Merck (MRK) Dips More Than Broader Market: What You Should Know

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt